Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
84 results about "Biliary fibrosis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is an autoimmune disease of the liver. It results from a slow, progressive destruction of the small bile ducts of the liver, causing bile and other toxins to build up in the liver, a condition called cholestasis.
Sulfonylurea derivative and pharmaceutical composition and application thereof
The invention relates to a preparation method and application of a sulfonylurea compound and a composition containing the same component as FXR and / or TGR5 agonist, the FXR and / or TGR5 agonist is a compound shown as a formula (I), or a pharmaceutically acceptable salt, a solvate, a prodrug, an isomer and a stable isotope derivative thereof. The compounds can be used for treatment of FXR and / or TGR5 mediated diseases including primary biliary cirrhosis, nonalcoholic fatty liver, portal hypertension, bile acid diarrhea and cholestasis, type II diabetes and obesity and other field.
Owner:SHANGHAI DE NOVO PHARMA
FXR agonist
PendingCN107021957AExcellent FXR receptor agonistic activityGood biological stabilityOrganic active ingredientsOrganic chemistryPrimary biliary cirrhosisFarnesoid X receptor
The invention relates to a compound shown as formula (I), a pharmaceutically acceptable salt, ester or stereoisomer thereof. R1, R2, R3, R4, m, n, W, A, Z, E, F, X and Y are defined as the specification. The invention also relates to a preparation method of the compounds, pharmaceutical preparations and application in drugs for treatment and / or prevention of FXR (farnesoid X receptor) mediated nonalcoholic fatty liver diseases, primary biliary cirrhosis, lipid metabolism disorders, diabetic complications, malignant tumors and other related diseases. (formula (I)).
Owner:XUANZHU BIOPHARMACEUTICAL CO LTD
FXR agonist
PendingCN107021958AExcellent FXR receptor agonistic activityGood biological stabilityOrganic active ingredientsNervous disorderPrimary biliary cirrhosisFarnesoid X receptor
The invention relates to a compound shown as formula (I), a pharmaceutically acceptable salt, ester or stereoisomer thereof. R1, R2, R3, R4, m, n, W, A, Z, E, F, X and Y are defined as the specification. The invention also relates to a preparation method of the compounds, pharmaceutical preparations and application in drugs for treatment and / or prevention of FXR (farnesoid X receptor) mediated nonalcoholic fatty liver diseases, primary biliary cirrhosis, lipid metabolism disorders, diabetic complications, malignant tumors and other related diseases. (formula (I)).
Owner:XUANZHU BIOPHARMACEUTICAL CO LTD
Sulphonylaminocarbonyl derivatives, and pharmaceutical compositions and use thereof
The invention relates to preparation methods of sulphonylaminocarbonyl derivatives and compositions containing the same component and a use of the sulphonylaminocarbonyl derivatives as FXR and / or TGR5 agonists; the agonists are the sulphonylaminocarbonyl derivatives represented by the formula I, or pharmaceutically acceptable salts, prodrugs, solvates, hydrates, polymorphs, isomers, and stable isotope derivatives thereof. The compounds can be used for treatment of diseases and symptoms mediated by FXR and / or TGR5 and other therapeutic fields, wherein the diseases and symptoms include primary biliary cirrhosis, nonalcoholic fatty liver, portal hypertension, bile acid diarrhea and cholestasis, type II diabetes and obesity.
Owner:SHANGHAI DE NOVO PHARMA
Application of norisoboldine in preparing medicament for treating autoimmune disease
InactiveCN101375850AOrganic active ingredientsImmunological disordersImmunologic disordersUlcerative colitis
The invention relates to the medicine filed, in particular to a medicinal purpose of norisoboldine. The medicinal purpose is characterized in that the norisoboldine can be used in the application of preparing drugs for the treatment of autoimmune diseases. The autoimmune diseases are: rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, multiple sclerosis, type-I diabetes, psoriasis, ulcerative colitis, Sjogren syndrome, scleroderma, polymyositis, chronic active hepatitis, mixed connective tissue disease, primary biliary cirrhosis, autoimmune hemolytic anemia and other diseases.
Owner:CHINA PHARM UNIV
SNP in KRT8 gene exon area and determination method thereof
InactiveCN103602671ALiver cirrhosis controlLiver transplantation success rate controlMicrobiological testing/measurementDNA/RNA fragmentationPrimary biliary cirrhosisNucleotide
The invention discloses a SNP in KRT8 gene exon area and determination method thereof, and the SNP locus with G / T polymorphisms (GG) is at 12563 site of the eighth exon area of the KRT8 gene and has nucleotide sequences SEQ ID NO:1 and SEQ ID NO:2. The invention also provides a determination method of the SNP locus, and research and development of the polymorphisms can be applied to researches in the aspect of primary biliary cirrhosis, for example, control of primary biliary cirrhosis attack and hepatic cirrhosis degree or improvement of liver transplantation success rate.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Method for breeding IL-12p40 (-/-) IL-2R alpha (-/-) mice used as hepatic fibrosis and primary biliary cirrhosis animal models
InactiveCN103749388ALow specificityStrong destructionAnimal husbandryPrimary biliary cirrhosisIl 12p40
The invention discloses a method for breeding IL-12p40 (- / -) IL-2R alpha (- / -) mice used as novel hepatic fibrosis and primary biliary cirrhosis animal models. The method includes steps of (1), performing cross breeding on IL-2R alpha (+ / -) mice and IL-12p40(- / -) mice to obtain IL-12p40(+ / -) IL-2R alpha (+ / -) mice by means of breeding; (2), performing cross breeding on IL-12p40(- / -) mice and the IL-12p40(+ / -) IL-2R alpha (+ / -) mice obtained in the step (1) to obtain IL-12p40(- / -) IL-2R alpha (+ / -) mice by means of breeding; (3), performing inbreeding on the IL-12p40(- / -) IL-2R alpha (+ / -) mice obtained in the step (2) and obtaining the identified IL-12p40(- / -) IL-2R alpha (- / -) mice. The method has the advantages that IL-12p40 is an important cell factor in the immune system of a patient, and functions and differentiation of CD4+T and CD8+T cells can be affected by the IL-12p40; IL-2R alpha is an alpha chain of an IL-2 receptor and plays a key role in keeping the balance of the immune system of the patient.
Owner:UNIV OF SCI & TECH OF CHINA
Pharmaceutical compositions for combination therapy
The present invention relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one lipid lowering agent (e.g., PPAR-alpha agonist, PPAR-delta agonist, PPAR-alpha and delta dual agonist, and / or statin). Also disclosed is use of the combination for the treatment or prevention of a FXR mediated disease or condition, such as primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), portal hypertension, bile acid diarrhea, NAFLD (nonalcoholic fatty liver disease), NASH (non-alcohol-induced steatohepatitis), and other chronic liver diseases. The combination of the present invention is useful for the treatment or prevention of conditions related to elevated lipid and liver enzyme levels. The present invention also relates to packs or kits including the pharmaceutical combination.
Owner:INTERCEPT PHARMA INC
Use of Adefovir or Tenofovir for Inhibiting Mmtv-Like Viruses Involved in Breast Cancer and Primary Biliary Cirrhosis
Owner:GILEAD SCI INC
Chinese medicine composition for treating autoimmune liver disease, and preparation method thereof
The invention discloses a Chinese medicine composition for treating an autoimmune liver disease. The Chinese medicine composition is prepared from the Chinese medicinal materials, namely rheum officinale, radix rubiae, fructus forsythia, herba siegesbeckiae, large-leaved gentian and liquorice. The invention also discloses a preparation method of the Chinese medicine composition and application of the Chinese medicine composition. The composition has the effects of clearing away heat and toxic materials, smoothing liver-gallbladder, and promoting blood circulation to remove blood stasis, and is mainly used for treating autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis.
Owner:THE FIFTH MEDICAL CENT OF CHINESE PLA GENERAL HOSPITAL
Farnesoid X receptor (FXR) stimulant
ActiveCN109320517AExcellent FXR receptor agonistic activityPrevent non-alcoholic fatty liver diseaseOrganic active ingredientsSenses disorderDiseaseStimulant
The invention belongs to the technical field of medicines, and particularly relates to a compound as shown in the formula (I), and pharmaceutically acceptable salt and ester or a stereisomer thereof.R1, R2, R3, M1, M2, m, n, Q, L, ring A, ring B and ring C are as defined in the specification. The invention further relates to a preparation method of the compounds, and application in preparing medicines for treating and / or preventing related diseases such as non-alcoholic fatty liver disease, primary biliary cirrhosis, lipid metabolism disorders, diabetic complication and malignant tumors mediated by an FXR. The formula (I) is shown in the description.
Owner:XUANZHU BIOPHARMACEUTICAL CO LTD
Identification of a novel retrovirus associated with primary biliary cirrhosis and autoimmune disorders
InactiveUS6468737B1Reduced responseReactivity is smallOrganic active ingredientsAntipyreticAutoimmune thyroiditisS syndrome
The present invention relates, first, to the discovery, identification, and characterization of novel nucleic acid molecules, that are associated with PBC, Sjögren's syndrome, scleroderma, SLE, autoimmune thyroiditis and various other connective tissue disorders. The novel nucleotide sequences of the present invention are retroviral in origin and are indicative of a PBC retrovirus which bears a strong correlation with PBC. The present invention is based, in part, on the Applicant's data which is the first evidence to suggest that PBC patient's tissue may harbor a transmissible agent. The association of a retroviral infectious agent with PBC was first demonstrated by Applicants in vitro by co-culture of periportal lymph nodes derived from patients at time of transplantation and healthy biliary epithelium cells. The Applicant's discoveries as described herein, report the characterization of PBC-associated infectious agent as retroviral as demonstrated by electron microscopy and immunoblot reactivity. In addition, Applicants have characterized novel nucleotide sequences which are associated with the PBC-associated retrovirus.
Owner:ALTON OCHSNER MEDICAL FOUND
Methods and compositions for treating psc (primary sclerosing cholangitis) or pbc (primary biliary cirrhosis) with Anti-cd3 immune molecule therapy
InactiveUS20150132289A1Easy to doImprove complianceImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsPrimary biliary cirrhosisAnti cd3
A method or composition comprising an anti-CD3 immune molecule for treatment of PSC (primary sclerosing cholangitis) or PBC (primary biliary cirrhosis) in a subject.
Owner:THERAPIX BIOSCI
Therapeutic agent for primary biliary cirrhosis
InactiveUS6339104B1Good effectGood treatment effectBiocidePeptide/protein ingredientsTherapeutic effectBULK ACTIVE INGREDIENT
Disclosed is a therapeutic agent for primary biliary cirrhosis, which contains L-alanine or a pharmaceutically acceptable salt thereof as the active ingredient. The effect of this therapeutic agent is to reduce serum total bilirubin and transaminase value, thereby effectively curing primary biliary cirrhosis. This therapeutic agent can be chronically administrated for a long period of time and exhibits an effect superior to that obtained in ordinary medical therapy.
Owner:THE CITY OF OSAKA +1
Alpha crystal form of obeticholic acid as well as preparation method, medicine composition and application thereof
InactiveCN105859818AEasy to operateGood reproducibilityOrganic active ingredientsOrganic chemistry methodsSolventPRIMARY BILIARY ATRESIA
The invention relates to an alpha crystal form of obeticholic acid and a preparation method thereof. The preparation method comprises the following steps: (a) fully dissolving obeticholic acid under a backflow state in a mixed solvent of toluene or toluene and another kind of solvent forming a homogeneous system; (b) cooling the obtained obeticholic acid solution, so the alpha crystal form of the obeticholic acid precipitates out from the solution; (c) separating the alpha crystal form of the obeticholic acid out from the solution; and (d) placing the alpha crystal form of the obeticholic acid under 30-70 DEG C and drying for 3-30 hours at reduced pressure or ordinary pressure. The prepared alpha crystal form of obeticholic acid has the characteristics of better stability, higher purity, stable moisture content and the like. Furthermore, the invention also relates to a medicine composition of the alpha crystal form and the application of the alpha crystal form in preparing medicines for treating hepatic diseases such as biliary atresia, cholestatic liver disease, chronic liver disease, primary biliary cirrhosis, alcoholic fatty liver, non-alcoholic fatty liver disease and the like.
Owner:SICHUAN RUIXIKANG BIOLOGICAL MEDICINE CO LTD
Specific autoantibody of PBC (primary biliary cirrhosis) and application
InactiveCN103044548ADiagnosis helpsAids in differential diagnosisImmunoglobulins against animals/humansBiological testingAnti-mitochondrial antibodyAntigen
The invention provides a specific autoantibody of the PBC and a corresponding antigen. RBE (relative biological effectiveness) TP (total protein) of cholangiocarcinoma cells is taken as the antigen of the specific autoantibody; an IB (immunoblotting) method is adopted to detect the serum of a PBC patient; an autoantibody aiming at protein with the molecular weight about 20kD is detected and named Sp20 antibody; and then the Sp20 antibody is separated and obtained from the serum of the PBC patient through two-dimensional electrophoresis. The invention further provides an application of the Sp20 antibody in preparation of a kit for PBC diagnosis. By means of research on the mechanism of the Sp20 antibody in PBC incidence, theoretical basis is provided for early diagnosis, early treatment and prognostic judgment of PBC patients, diagnosis for AMA (anti mitochondrial antibody)-negative PBC patients is facilitated, and differential diagnosis with other autoimmune diseases is facilitated.
Owner:PEOPLES HOSPITAL PEKING UNIV
Efficient amplifying and culturing method for biliary epithelial cells
InactiveCN103031270AHigh purityPromote proliferationVertebrate cellsArtificial cell constructsEnzyme Inhibitor AgentBiliary tract
The invention discloses an efficient amplifying and culturing method for biliary epithelial cells in rabbit livers and belongs to the technical field of biological medicines. The efficient amplifying and culturing method comprises the following steps of: (1) separating, purifying and culturing the epithelial cells; (2) detecting cell growth lines; and (3) identifying the epithelial cells. The efficient amplifying and culturing method for the biliary epithelial cells, disclosed by the invention, has the advantages as follows: through a multi-step separating method, biliary epithelial cells with higher purities are obtained and a long-time multiplication culturing system for the biliary epithelial cells is established; a fact that the multiplication of the biliary epithelial cells in the livers can be obviously promoted through an Rho kinase inhibitor Y-27632 is first found; and the efficient amplifying and culturing method for the biliary epithelial cells, disclosed by the invention, has the advantages of simpler operation and the like, is suitable for promotion and application and can provide a platform for researches on a plurality of disease mechanisms including biliary atresia, primary biliary cirrhosis and the like.
Owner:SHAOXING UNIVERSITY
Specific autoantigen of primary biliary cirrhosis (PBC) and application thereof
InactiveCN104292322AHigh sensitivityImprove featuresDisease diagnosisBiological testingDiseasePrimary biliary cirrhosis
The invention discloses a specific autoantigen EIF2C1 of primary biliary cirrhosis (PBC). According to the specific autoantigen of PBC and the application thereof, six novel autoantigens of PBC are obtained through screening; during the detection on the blood serum of a PBC patient, the positive rate of each autoantigen reaches over 15%, so that the new-found autoantigens are potential biomarkers which are used for accurately diagnosing PBC through distinguishing other autoimmune diseases.
Owner:PEKING UNION MEDICAL COLLEGE HOSPITAL CHINESE ACAD OF MEDICAL SCI +1
Methods and Compositions for Diagnosis of Inflammatory Liver Disease
ActiveUS20150219664A1Easy diagnosisGood differential diagnosisOrganic active ingredientsHealth-index calculationPrimary biliary cirrhosisLiver disease
The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (E3) levels, either alone or with levels of eotaxin-1 (E1), and optionally, with levels of CCL22 and, further optionally, with levels of IL15. These levels can be used to facilitate a diagnosis of a liver disease of at least one of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), and / or to facilitate a differential diagnosis between AIH, PBC, and PSC. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject.
Owner:MEDIZINISCHE HOCHSCHULE HANNOVER +1
Farnesoid X receptor (FXR) stimulant
ActiveCN109320509AExcellent FXR receptor agonistic activityPrevent non-alcoholic fatty liver diseaseOrganic active ingredientsSenses disorderDiseaseStimulant
The invention belongs to the technical field of medicines, and particularly relates to a compound as shown in the formula (I), and pharmaceutically acceptable salt and ester or a stereisomer thereof.R1, R2, R3, R4, W, A, Z, E, X, Y and n are as defined in the specification and the claims. The invention further relates to a preparation method of the compounds, pharmaceutical preparation and application in preparing medicines for treating and / or preventing related diseases such as non-alcoholic fatty liver disease, primary biliary cirrhosis, lipid metabolism disorders, diabetic complication andmalignant tumors mediated by an FXR. The formula (I) is shown in the description.
Owner:XUANZHU BIOPHARMACEUTICAL CO LTD
Traditional Chinese medicine for treating primary biliary cirrhosis and preparation method and application of traditional Chinese medicine
InactiveCN107519430ASimple recipeGood effectDigestive systemUnknown materialsOverlapping syndromePrimary biliary cirrhosis
The invention discloses a traditional Chinese medicine for treating primary biliary cirrhosis and a preparation method and application of the traditional Chinese medicine. The traditional Chinese medicine comprises the following raw materials in parts by weight: 500-1500 parts of oriental wormwood, 1000-2500 parts of roots of common peony, 500-1000 parts of scorpio, 1000-2000 parts of cortex dictamni, 1000-2500 parts of malt and 500-2000 parts of licorice roots. The traditional Chinese medicine disclosed by the invention has the main effects of clearing heat and removing toxin, soothing livers and dispersing gallbladder as well as activating blood and removing stasis, is capable of treating overlap syndromes of primary biliary cirrhosis caused by endoretention of damp heat, liver and gall stasis and Qi-stagnancy and blood stasis, and is simple in composition formula, outstanding in medicinal effect, free of toxic or side effect and convenient to prepare.
Owner:YUNNAN UNIV OF TRADITIONAL CHINESE MEDICINE
Colloidal gold chromatography anti-Sp100 antibody detection test paper and preparation method thereof
ActiveCN102621313AHigh detection sensitivityReduce manufacturing costMaterial analysisCelluloseSp100 Antibody
Owner:SHANGHAI KEXIN BIOTECH
FXR (farnesol X receptor) agonist
ActiveCN109575008AExcellent FXR receptor agonistic activityPrevent non-alcoholic fatty liver diseaseOrganic active ingredientsSenses disorderDiseaseDiabetic complication
The invention belongs to the technical field of medicine and particularly relates to a compound shown as formula (I) that is shown in the description, and its pharmaceutically acceptable salts, estersor stereoisomers, with R1, R2, R3, M1, M2, Q, L, ring A, ring B and m defined as in the description and the claims. The invention also relates to a preparation method these compounds, pharmaceuticalpreparations and their application in the preparation of drugs for the treatment and / or prevention of FXR-mediated non-alcoholic fatty liver disease, primary biliary cirrhosis, lipid metabolism disorder, diabetic complications, malignant tumors and related diseases.
Owner:XUANZHU BIOPHARMACEUTICAL CO LTD
FXR receptor agonist
ActiveCN109265471AExcellent FXR receptor agonistic activityPrevent non-alcoholic fatty liver diseaseOrganic active ingredientsSenses disorderDiseaseDiabetic complication
The present invention discloses an FXR receptor agonist, belongs to the technical field of medicine, and particularly relates to a compound represented by a formula (I), a pharmaceutically acceptablesalt, an ester or a stereoisomer thereof, wherein R<1>, R<2>, R<3>, M, L, L1, W, A , B, Q, m and n are defined in the specification. The present invention further relates to a preparation method of the compound, a pharmaceutical preparation, and applications in preparation of drugs for treatment and / or prevention of nonalcoholic fatty liver disease, primary biliary cirrhosis, lipid metabolism disorder, diabetic complication, malignant tumors and other related diseases mediated by FXR receptors. The formula I is defined in the specification.
Owner:XUANZHU BIOPHARMACEUTICAL CO LTD
Traditional Chinese medicine for treating primary biliary cirrhosis
InactiveCN103356886ASafe and effective in primary biliary cirrhosisNo significant differenceDigestive systemPlant ingredientsPrimary biliary cirrhosisClinical tests
The invention relates to a traditional Chinese medicine for treating primary biliary cirrhosis, which is prepared from the following medicinal materials in parts by weight: 12 parts of fructus rosae laevigatae, 14 parts of radix scrophulariae, 6 parts of euphorbia jolkinii, 10 parts of beggarweed, 12 parts of climbing entada, 14 parts of elsholtzia rugulosa hemsl, 10 parts of michelia champaca, 14 parts of radix bupleuri, 10 parts of semen cassiae, 8 parts of rhizoma cyperi, 14 parts of semiliquidambar cathayensis, 10 parts of abutilon peniculatum flower, 14 parts of dysosma difformis, 12 parts of osbeckia chinensis, 14 parts of penthorum chinense pursh, 10 parts of twisted-stalk, 8 parts of all-grass of winkled marshweed, 10 parts of bryoniifolia root and 10 parts of gynura divaricata. Clinical tests prove that the traditional Chinese medicine disclosed by the invention can safely and effectively treat primary biliary cirrhosis.
Owner:丁漫漫
Method for analyzing primary biliary cirrhosis metabolite based on H1NMR technology
InactiveCN102323286AReasonable designAnalysis using nuclear magnetic resonanceMetaboliteOriginal data
The invention provides a method for analyzing primary biliary cirrhosis metabolites based on H1NMR technology, belongs to the field of biotechnology, and relates to primary biliary cirrhosis. The invention mainly comprises the following flow: step 1, sample collection and preparation, liver function testing; step 2, extraction, alignment, and normalization of original data; step 3, primary component analysis (PCA); step 4, orthogonal partial least squares-discriminant analysis (OPLS-DA); step 5, searching of metabolites causing intergroup differences; steo 6, statistical test. The advantages of the invention are that: the analysis method provided by the invention provides a new approach and method for the analysis research of primary biliary cirrhosis metabolites; the method has reasonable and feasible design, provides new landmarks for the research of the diagnosis and treatment of PCB, and also provides new thoughts for the research of the pathogenesis.
Owner:SHANGHAI CLUSTER BIOTECH
Preparation method of high-purity natural ursodesoxycholic acid and application thereof in medicament
The invention belongs to the technical field of medical biology, in particular to a preparation method of high-purity natural ursodesoxycholic acid. The high-purity natural ursodesoxycholic acid is obtained by separating and purifying bear gall powder prepared from a manual drained bear gall, and the high performance liquid chromatography purity is not lower than 98 percent. The preparation method comprises the following steps of: firstly, separating and purifying by applying a cation exchange medium to prepare tauroursodeoxycholic acid with purity not lower than 90 percent; and then thoroughly hydrolyzing the tauroursodeoxycholic acid into ursodesoxycholic acid and taurine in the presence of alkali and separating and purifying by applying a silica gel adsorption chromatography technology to prepare the ursodesoxycholic acid with purity not lower than 98 percent. The natural ursodesoxycholic acid prepared by the invention has the effects on treating primary biliary cirrhosis and primary sclerosing cholangitis.
Owner:重庆寰瑞生物技术有限公司
Deuterated chenodeoxycholic acid derivative and pharmaceutical composition comprising compound thereof
ActiveUS20180030083A1Improve the activation effectPharmacodynamics/pharmacokinetic propertyOrganic active ingredientsAntipyreticChenodeoxycholic acidCholesterol cholelithiasis
Disclosed are deuterated chenodeoxycholic acid derivatives and pharmaceutical compositions containing the deuterated chenodeoxycholic acid derivatives. In particular, disclosed is a deuterated chenodeoxycholic acid derivative of formula (I), or a crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, and a pharmaceutical composition containing the same. The deuterated chenodeoxycholic acid derivatives of formula (I) can be used to treat and / or prevent diseases related to the farnesoid X receptor (FXR) and / or G-protein coupled bile acid receptor, such as nonalcoholic steatohepatitis, nonalcoholic fatty liver diseases, gallstones, primary biliary cirrhosis, and cirrhosis.
Owner:SUZHOU ZELGEN BIOPHARML
Methods and compositions for diagnosis of inflammatory liver disease
ActiveUS9535071B2Good differential diagnosisDiagnosis can be complexHealth-index calculationDigestive systemPrimary biliary cirrhosisInflammatory bowel disease
The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (E3) levels, either alone or with levels of eotaxin-1 (E1), and optionally, with levels of CCL22 and, further optionally, with levels of IL15. These levels can be used to facilitate a diagnosis of a liver disease of at least one of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), and / or to facilitate a differential diagnosis between AIH, PBC, and PSC. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject.
Owner:MEDIZINISCHE HOCHSCHULE HANNOVER +1
Diagnosis of gluten sensitive enteropathy and other autoimmunopathies
InactiveUS7781169B1Increased riskReduce the overall heightDisease diagnosisBiological testingInsulin dependentRheumatism
Method for diagnosis of autoimmune diseases of the GSE-type or associated with gluten sensitive enteropathy comprising taking a sample and testing the sample for antibodies against human tissue transglutaminase, tissue-specific transglutaminases, or other transglutaminases. It was found that autoimmune diseases other than celiac disease can be diagnosed and distinguished in this way, notably, dermatitis herpetiformis Duhring, Crohn's disease, Addison's disease, AI hemolytic anemia, AI thrombocytopenic purpura, AI thyroid diseases, atrophic gastritis—pernicious anemia, IgA nephropathy or IgA glomerulonephritis, myasthenia gravis, partial lipodystrophy, polymyositis, primary biliary cirrhosis, primary sclerosing cholangitis, recurrent pericarditis, relapsing polychondritis, rheumatoid arthritis, rheumatism, sarcoidosis, Sjögren's syndrome, SLE, splenic atrophy, type I (insulin-dependent) diabetes mellitus, diabetes mellitus of other types, ulcerative colitis, vasculitis (both systemic and cutaneous), vitiligo as well as autoimmune diseases associated with infertility, increased risk of abortion, or reduced fetal growth.
Owner:PAULSSON MATS +5
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com